Partners in Health

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

2 marketed ·

Quick facts

Marketed products

sofosbubir/velpatasvir · Virology/Hepatology
Sofosbuvir inhibits hepatitis C virus NS5B polymerase while velpatasvir inhibits NS5A protein, together blocking viral replication.
sofosbubir/velpatasvir/voxilaprevir · Infectious Disease / Virology
This combination inhibits three different hepatitis C virus enzymes (NS5B polymerase, NS5A protein, and NS3/4A protease) to block viral replication.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Partners in Health portfolio CI brief
Partners in Health pipeline updates RSS

Frequently asked questions about Partners in Health

What are Partners in Health's marketed drugs?

Top marketed products include sofosbubir/velpatasvir, sofosbubir/velpatasvir/voxilaprevir.

sofosbubir/velpatasvir · Virology/Hepatology
sofosbubir/velpatasvir/voxilaprevir · Infectious Disease / Virology
Sector hub: All tracked pharma companies